BioMedPartners raises CHF95m for second healthcare venture fund
Fund
BioMedPartners has reached a first closing of BioMedInvest II LP on CHF95m, with a target of CHF 120m or more. The fund has a lifespan of ten years with possible extensions. The Guernsey-based fund will remain open for additional new investors for some months. Terms and conditions are described as industry standard. Legal advice was provided by Collas Day.
Investors
The fund is backed by both existing and new investors, including the lead investor ERP-EIF Dachfonds. Further investors include pharmaceutical companies, pension funds and banks, and mainly hail from Germany and Switzerland.
Investments
The fund will invest in early- to later-early-stage private companies and spin-offs in the biotechnology, emerging pharmaceutical, medical technology and other healthcare-related industries such as diagnostics or platform technologies with a geographic focus on Switzerland, Austria, Germany, Italy, Liechtenstein and France. The firm states that these companies offer significant return potential, as large pharma companies are increasingly acquiring biotech firms to fill their product pipelines.
The amount the firm plans to invest over the lifetime of its portfolio companies is about CHF 1-12m and it foresees investing in 15-18 companies over five years. BioMedInvest typically plays the lead or co-lead investor role, structuring the transaction and syndicating with other venture capital firms.
People
Dr Markus Hosang, Dr Gerhard Ries and Thomas Moller are the main managers of the fund and are supported by a team of four investment professionals. BioMedPartners, founded in 2003, has raised over CHF240m until today and invested in more than 25 companies.
Name: BioMedInvest II
Target: CHF 120m
Closed on: CHF 95m
Focus: Early-stage, venture
Contacts: Dr Markus Hosang, Dr Gerhard Ries, Thomas Moller
Address: BioMedPartners
Elisabethenstr. 23
CH-4051 Basel
Tel: +41 61 270 3535
Fax: +41 61 270 3500
Advisers: Collas Day (Legal).
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds








